罗格列酮治疗2型糖尿病的机制及临床疗效  

Mechanism and clinical efficacy of rosiglitazone in treating type 2 diabetes

作　　者：朱耀国[1] 任叶慧[1] 姜军权[1] 

机构地区：[1]中国人民解放军457医院内分泌科,湖北武汉430012

出　　处：《中国新药与临床杂志》2003年第12期751-753,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：2型糖尿病的根本病因是胰岛素抵抗和B细胞功能损害。传统的治疗方法不能针对糖尿病病因 ,因而无法实现血糖的长期控制。罗格列酮则能显著降低胰岛素抵抗并改善B细胞功能 ,从而持久稳定地控制糖尿病。The basic cause of type 2 diabetes is the insulin resistance and the beta cells dysfunctional. Rosiglitazone can improve insulin sensitivity, protect the function of pancreatic B cells and steadily control the blood glucose. This article explains the mechanism and clinical efficacy of rosiglitazone in treating type 2 diabetes mellitus.

关 键 词：降血糖药 罗格列酮 糖尿病 非胰岛素依赖型 药物评价 药理学 

分 类 号：R587.1[医药卫生—内分泌] R977.15[医药卫生—内科学]